Biologics vs DMARDs

What the research found.

• One review pooled 21 trials and 8361 people with early rheumatoid arthritis. Adalimumab with methotrexate led on remission, at an odds ratio of 2.90, with the true value somewhere from 1.94 to 4.33. Only one drug showed a safety signal across the whole set.

  Xu and colleagues, BMC Rheumatology, 2025

• One trial gave 353 people either three older tablets together or methotrexate with a biologic, and disease activity scores came out level. At a year, 78 percent were still on the tablets against 63 percent on the biologic route. The P value for the direction of switching was 0.005.

  Peper and colleagues, Arthritis Care and Research, 2017

• One trial started 799 people who had never had methotrexate. At a year, 62 percent on adalimumab with methotrexate hit the response target, against 46 percent on methotrexate alone and 41 percent on adalimumab alone. Both comparisons came in at P under 0.001.

  Breedveld and colleagues, Arthritis and Rheumatism, 2006

• One meta-analysis pooled 30 trials and 3858 people on methotrexate with folic acid. Anemia of any degree turned up in 2.55 percent and a low white cell count in 1.17 percent. Across all of them there were four severe anemias and three severe low neutrophil counts.

  Vanni and colleagues, Rheumatology, 2020

• One study tracked 7089 Australians in ordinary practice. People stayed on upadacitinib a median of 26.6 months, from 24.9 to 30.8, against 13.3 months on tumor necrosis factor blockers, from 11.5 to 14.5. That study watched what happened rather than assigning anybody to anything.

  Youssef and colleagues, Rheumatology and Therapy, 2025

The short answer.

These aren't rival products, they're two steps in one plan. Almost everybody starts on a tablet, usually methotrexate, and a biologic comes in when that isn't enough. So the real question is never which is better, it's what the next move should be when the first one falls short.

In early disease the trials favor adding a biologic. One review pooled 21 trials and 8361 people, where several biologics with methotrexate beat methotrexate alone on remission. One older trial found the outcome the same way round, with 62 percent hitting the response target on the pair against 46 percent on methotrexate alone.

After methotrexate has already failed, the picture changes. One trial gave people either three older tablets or methotrexate plus a biologic, disease activity came out level, and people stayed on the three tablets longer. The authors point at the cost difference and argue the tablets deserve first place.

So the honest answer is that it depends where you are. Early on, adding a biologic has the better evidence, and later, three cheap tablets have a real case. Your team weighs your organs, your other illnesses, and what you can get hold of, and a trial captures none of those.

Side by side.

They aren't rivals

It's tempting to read this as two products competing for the same job, and that isn't how they get used. They sit at different points in one plan, and the plan is what decides the order. Almost everybody starts on a tablet, usually methotrexate.

A biologic comes in when that tablet isn't holding the disease down, whether that's the tablet on its own or the tablet alongside others. So the question is never which class is better in the abstract. It's what the next move should be when the first one falls short, and the trials answer that differently depending on how early you ask it.

Early disease favors adding a biologic

One review pooled 21 trials and 8361 people with early rheumatoid arthritis, and several biologics beat methotrexate on its own. Two led the field on two different measures. Adalimumab with methotrexate led on remission, at an odds ratio of 2.90, with the true value somewhere from 1.94 to 4.33.

Tocilizumab with methotrexate led on the strictest response measure, at 4.41, from 2.29 to 8.49. Only one combination showed a safety signal, and it was tocilizumab with methotrexate, at an odds ratio of 5.11. So the drug that led one measure is also the one with the safety signal against it, and both belong in the same sentence.

An older trial makes the point more plainly. It started 799 people who had never taken methotrexate on one of three routes, and at a year 62 percent on adalimumab with methotrexate hit the response target, against 46 percent on methotrexate alone and 41 percent on adalimumab alone. Both comparisons came in at P under 0.001.

Joint damage moved in the direction you would expect from that. After two years it had moved 1.9 units on the pair, against 10.4 units on methotrexate alone and 5.5 on adalimumab alone. Side effects looked alike in all three arms.

Later on, the tablets hold their ground

Now change the question, because somebody who is already on methotrexate and finding it isn't enough is asking something else entirely. One trial put that to the test in 353 people. Half got three older tablets together and half got methotrexate plus a biologic.

Anyone not improving at 24 weeks swapped to the other arm, and 289 of them were then followed in an open-label extension for up to 72 more weeks. Disease activity scores came out level in both arms and stayed stable. What differed was staying power rather than disease control.

At a year, 78 percent were still on the three tablets against 63 percent on the biologic route, and more people moved from the biologic route to the tablets than the other way, at P equals 0.005. The authors draw the conclusion themselves, pointing at the cost difference and at the similar outcomes. On that basis they argue the older combination has a case as the first choice after methotrexate falls short.

What the two findings really compare

Those two results look contradictory and they aren't, and the way to see it is to look at what sits on each side of the comparison. The number of drugs is what differs. The early-disease trials compare two drugs against one, and the later trial compares three drugs against two.

So part of what reads as a biologic advantage is something else, which is the advantage of taking more than one drug at a time. That's worth holding onto, because the combinations cost wildly different amounts. Three old tablets and one biologic are very different purchases, and when the trial matched three tablets against methotrexate plus a biologic, the disease control came out equal.

The pairing question

If a biologic is chosen, something usually goes alongside it, and which tablet turns out to count for more than people expect. The trials show it changes the result. One review looked at just that question.

Alongside rituximab, a good response at six months was more common on leflunomide than on methotrexate, at a risk ratio of 1.38, from 1.13 to 1.68, at P equals 0.001, across 2078 people. Side effect rates were alike between the two. So the pairing there runs against the tablet most people assume.

Alongside a tumor necrosis factor blocker it ran the other way, where a tablet other than methotrexate gave a worse response at a risk ratio of 0.93, from 0.87 to 1.0, and people stayed on it less too. Alongside abatacept the two were alike. For tocilizumab and the newer targeted tablets, too few trials existed to pool at all.

Working against staying on it

One habit is worth building here, because these trials measure two separate things and people read them as one. How well a drug controls the disease is one measurement, and how long people keep taking it is a second. They often disagree, and the disagreement is usually the interesting part.

Take the trial of three tablets against a biologic, where the two arms tied on disease control and the tablets won on staying power. Take a different trial that put people on methotrexate or leflunomide after both together had worked. Remission rates came out similar, at P equals 0.091, and staying on the drug did not, at 81 percent against 55 percent, at P equals 0.025.

Ordinary practice shows the split running the other way. A study tracked 7089 Australians, where people stayed on upadacitinib a median of 26.6 months, from 24.9 to 30.8, against 13.3 months on tumor necrosis factor blockers, from 11.5 to 14.5. That study watched what happened rather than assigning anybody, and a newer drug also reaches prescribers already inclined to stick with it.

What the monitoring looks like

Neither class is a drug you take and forget about, and both come with regular blood tests. The reasons differ a little by drug. For methotrexate the figures are on file and worth seeing.

One review pooled 30 trials and 3858 people taking it with folic acid, where anemia of any degree turned up in 2.55 percent, a low white cell count in 1.17 percent, and a low neutrophil count in 1.77 percent. Across all 3858 people there were four severe anemias and three severe low neutrophil counts. There were no cases where every blood line fell at once.

The authors call blood count problems an uncommon side effect at this dose with folic acid. So the tests happen because the problem is real and rare, rather than because anybody expects trouble from them. That's a different thing from a reason to worry.

What to ask

No page can tell you which is right for you, and the questions to ask are the useful part anyway. Ask where you are in the sequence, because the evidence differs between early disease and later. After methotrexate has fallen short, it reads differently.

Ask whether three tablets together are an option before a biologic, and if a biologic is chosen, ask which tablet goes alongside it and why that one. Then ask the question people skip, which is what the plan is if this step doesn't work either. Knowing the next two moves makes the current one easier to commit to.

When each one fits.

• Almost everyone starts on a tablet, usually methotrexate, which earns its place, so ask what the plan is if it isn't enough.
• In early, aggressive disease the trials favor a biologic with methotrexate over methotrexate alone, at 62 percent hitting the target against 46 percent.
• After methotrexate falls short, three tablets together are a real option, because one trial found disease control level with a biologic and more people still taking the tablets at a year.
• Ask which tablet is being paired with which biologic, because alongside rituximab, leflunomide beat methotrexate at a risk ratio of 1.38, from 1.13 to 1.68.
• Don't read staying on a drug as proof the drug is working, because trials measure the two separately and they often disagree.
• Bring up cost if it's a factor for you, since the trial authors do, and it's part of why the older combination keeps its place.

Questions patients ask.